

CDC Coronavirus Disease 2019 Response


U.S. COVID-19 Epidemiology

Sara Oliver MD, MSPH




ACIP Meeting June 24, 2020

For more information: www.cdc.gov/COVID19



Outline

- Overview of U.S. COVID-19 Epidemiology
- Epidemiology among Healthcare Personnel
- Epidemiology among Long Term Care Facility (LTCF) Residents
- Epidemiology among Children
- Epidemiology among Pregnant Women
- Epidemiology among People in Congregate Settings
- Serology






• • • •

Overview of U.S. COVID-19 Epidemiology



United States COVID-19 Cases by County

January 21 to June 23, 2020



Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020

- 1,761,503 aggregate U.S. cases of COVID-19 in this report
- Hospitalizations were 6 times higher among patients with reported underlying conditions than those without underlying conditions
- Deaths were 12 times higher among patients with underlying conditions
- Clinical outcomes varied by sex:
 <u>Males</u>

Hospitalized: **16**% Admitted to the ICU: **3**% Died: **6**%

Females


Hospitalized: **12**% Admitted to the ICU: **2**% Died: **5**%



https://www.cdc.gov/mmwr/volumes/69/wr/mm6924e2.htm?s_cid=mm6924e2_w


Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020

FIGURE. Daily number of COVID-19 cases^{*}^{†,§,¶} (A) and COVID-19-associated deaths** (B) reported to CDC — United States, January 22-May 30, 2020




Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020

FIGURE. Daily number of COVID-19 cases^{*,†,§,¶} (A) and COVID-19-associated deaths^{**} (B) reported to CDC — United States, January 22-May 30, 2020



Public Health Laboratories Reporting to CDC


March 1 to June 13, 2020





Commercial Laboratories Reporting to CDC

March 1 to June 13, 2020







Percent of Visits for ILI and CLI in Emergency Departments

National Syndromic Surveillance Program (NSSP)

September 29,2019 to June 13, 2020



Pneumonia, Influenza and COVID-19 Mortality NCHS Mortality Reporting System



https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html

NCHS = National Center for Health Statistics

11

COVID-NET: Hospitalization Surveillance from 14 States

States participating in COVID-NET



Surveillance network collecting hospitalization data


- Catchment area ~10% of US population
- Patients must be a resident of the surveillance area and have a positive SARS-CoV-2 test within 14 days prior to or during hospitalization
- Charts reviewed by trained surveillance officers

MMWR April 17, 2020 COVID-NET = COVID-19-Associated Hospitalization Surveillance Network

https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm

COVID-NET: Hospitalization Surveillance from 14 States

Cumulative Hospitalization Rate




Calendar Week End Date (MMWR Week No.)



March 1 to June 13, 2020


COVID-NET: Age-adjusted COVID-19-associated hospitalization rates, by race and ethnicity March 1 to June 13, 2020





COVID-NET: Age-adjusted COVID-19-associated hospitalization rates, by race and ethnicity

March 1 to June 13, 2020




COVID-NET: Hospitalization Surveillance from 14 States

March 1 to June 13, 2020

Underlying Medical Conditions Among Adults

60



91.2% of hospitalized adults reported an underlying condition


Hypertension: 56% Obesity: 49% Metabolic Disease (including Diabetes): 42% Cardiovascular Disease: 33%



7,465 hospitalized adults with available information

https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html 16

COVID-NET: Hospitalization Surveillance from 14 States



150 hospitalized children with available information

https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html 17

Risk Factors for Hospitalization

Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020

- 220 hospitalized and 311 non-hospitalized COVID-19 patients from 6 metropolitan Atlanta hospitals/clinics
- Several factors independently associated with hospitalization, through adjusted Odds Ratios (aORs)*
 <u>Risk Factors</u> <u>aOR</u>



	, 0
Risk Factors	<u>aOR</u>
Age ≥65 years	3.4 (1.6-7.4)
Black race	3.2 (1.8-5.8)
Having diabetes mellitus	3.1 (1.7-5.9)
Lack of insurance	2.8 (1.1-7.3)
Male sex	2.4 (1.4-4.1)
Smoking	2.3 (1.2-4.5)
Obesity	1.9 (1.1-3.3)




*Adjusted for age, sex, race, obesity, past or current smoking, insurance status, and other underlying conditions MMWR June 17, 2020 <u>https://www.cdc.gov/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_w</u> COVID-19 Epidemiology among Healthcare Personnel



Healthcare Personnel (HCP)

Characteristics of Health Care Personnel with COVID-19 — United States, February 12–April 9, 2020

CDC COVID-19 Response Team



- Among 1,423 HCP patients who reported contact with a lab-confirmed COVID-19 patient in either healthcare, household or community settings, 780 (55%) reported having such contact only in health care setting within 14 days
- Most HCP not hospitalized
- Severe outcomes occurred across all age groups
 - 27 (of 4407: 0.6%) deaths

MMWR April 17, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e6.htm?s_cid=mm6915e6_w

Healthcare Personnel (HCP)

 CDC reports and routinely updates cases and deaths among healthcare personnel on the CDC website

Cases & Deaths among Healthcare Personnel

As of June 23st

Data were collected from 1,952,346 people, but healthcare personnel status was only available for 424,304 (21.7%) people. For the 83,673 cases of COVID-19 among healthcare personnel, death status was only available for 53,902 (64.4%).

> CASES AMONG HCP 83,673

DEATHS AMONG HCP




Next Steps: Healthcare Personnel (HCP)



- Prospective cohort study of 1,600 HCP working in US Emergency Departments (ED)
 - Estimate attributable risk of occupational acquisition of COVID-19 infection for emergency physicians and nurses
 - Estimate attributable risk of occupational acquisition of COVID-19 infection related to **endotracheal intubation**
 - Identify risk factors associated with SARS-CoV-2 transmission during intubation
 - Determine the **prevalence** of symptomatic and asymptomatic COVID-19 infections occurring in ED HCPs
- Serial symptom questionnaires, SARS-CoV-2 serology (IgG) and self-collected nasal swabs (PCR) over a 12-week period



Next Steps: Healthcare Personnel (HCP)



- Emerging Infections Program (EIP): network of 10 state health departments and local public health and academic partners
- EIP sites initiated projects on HCP COVID-19 case tracking
 - Surveillance for and interviews of HCP cases (10 EIP sites)
 - Comparison of HCP cases and HCP non-cases (5 EIP sites)
- As of 6/12, **1,044** cases reported among HCP from 9 sites, 425 interviews conducted



Next Steps: Healthcare Personnel (HCP)

	AZ HEROES	RECOVER
	Collaboration between University of Arizona, CDC and NCI	CDC
Study Population	HCP, first responders, essential and frontline workers	HCP, first responders with direct contacts with patient and public with COVID-19
Study Design	Prospective longitudinal cohort	Cohort
Timeline	12 months	12 months
Specimen Collection	Repeat PCR and serology	Repeat PCR and serology
Objectives	Determine incidence of asymptomatic and symptomatic infection Estimate incidence of novel infection and repeat infection	Determine incidence of asymptomatic and symptomatic infection, with a focus on the clinical epidemiology and impact on missed work, presenteeism and functioning Immune response to SARS-CoV-2 infection



AZ HEROES: Arizona Healthcare, Emergency Response and Other Essential Workers Surveillance Study RECOVER: Research on the Epidemiology of COVID-19 in Emergency Response and Healthcare Personnel 24



COVID-19 Epidemiology among Long Term Care Facility (LTCF) Residents

• • • •

Long Term Care Facilities: Skilled Nursing Facility, King County, Washington

• As of March 18th, **167** confirmed COVID-19 cases associated with the facility




- 86% of tested residents were confirmed positive
- **34%** of residents died



MMWR March 27, 2020 <u>https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e1.htm?s_cid=mm6912e1_w</u> McMichael TM, et al. NEJM 2020

Long Term Care Facilities

- Reports suggest that once COVID-19 has been introduced into a long-term care facility, it has the potential to result in high attack rates among residents, staff members, and visitors.
- Many areas contribute to vulnerability of LTCFs:
 - Inadequate familiarity with PPE
 - Inadequate supplies of PPE
 - High prevalence of underlying conditions
 - Atypical presentations in elderly
 - Facilities share staff and patients





Long Term Care Facilities



- As of the week ending June 7, almost 15,000 nursing homes are reporting COVID-19 in NHSN
 - These facilities reported over **107,000** confirmed COVID-19 cases, over 71,000 suspected cases and almost 30,000 deaths in residents
 - CMS began publicly reporting data from nursing homes on June 4, 2020
- CDC also tracks what states report publicly; these numbers include a broader range of LTCFs beyond nursing homes, such as assisted living facilities
- As of June 11, 2020, there were at least 245,605 cumulative confirmed or probable COVID-19 cases in residents and staff from 10,708 LTCFs across 51 U.S. states and territories based on state health department websites and other publicly available information



Next Steps: Long Term Care Facilities

- Information collected through NHSN will be used to:
 - Strengthen COVID-19 surveillance locally and nationally
 - Monitor trends in infection rates
 - Help local, state, and federal health authorities get help to nursing homes faster



COVID-19 Module for LTCF





COVID-19 Epidemiology among Children



. . .

COVID-19: Infants and Children

- Children may have different or minimal symptoms
 - Abdominal pain or GI symptoms¹
- May be more likely to be asymptomatic^{1,2}
- Early in the outbreak in China, school-aged children had largest number of close contacts of any age³
- Efficiency of spread in schools by children is unknown. Existing data are reassuring, but limited⁴⁻⁶

¹MMWR April 10, 2020 <u>https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e4.htm?s_cid=mm6914e4_w</u>



²Dong et al. Pediatrics. June 2020
³Zhang et al. Science April, 2020
⁴Heavey et al. Eurosurveillance May 2020

⁵Johansen et al. Eurosurveillance May 2020 ⁶COVID-19 in schools- the experience in NSW April 2020 Report




Inflammatory Multisystem Syndrome in Europe

- Primarily described among children
- Initially called PIMS (Pediatric Inflammatory Multisystem Syndrome) in Europe

March-17 May (n = 108)

Kawasaki-like disease and cardiac involvement

Epidemic curve peaked **4-5** weeks after peak of COVID-19 epidemic in France



Temporal distribution of COVID-19 hospitalisations and SARS-CoV2 hyperinflammatory paediatric cases, France, 2



Inflammatory Multisystem Syndrome in Europe

- Pediatric Inflammatory Syndrome in England: March 23 to May 16
 - **58** children with fever and laboratory evidence of inflammation
 - SARS-CoV-2 PCR positive 15/58 (26%) children
 - SARS-CoV-2 IgG positive in 40/46 (87%) children
 - All patients presented with persistent fever (3-19 days)
 - Abdominal pain n=31/58, 53%
 Rash n=30/58, 52%



29 (50%) children developed shock and myocardial dysfunction
8 (14%) children developed coronary artery dilation or aneurysm
2 (3%) children required extracorporeal membrane oxygenation (ECMO)

45/58 (**78**%) had

evidence of current or

prior SARS-CoV-2

infection

Multisystem Inflammatory Syndrome in Children (MIS-C) Case definition among children aged <21 years

• Fever > 38.0°C

AND

- Laboratory evidence of inflammation
 AND
- Evidence of clinically severe hospitalized illness with multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological)

AND

- One of the following:
 - 1. SARS-CoV-2 positive PCR test
 - 2. SARS-CoV-2 positive antibody test
 - 3. SARS-CoV-2 negative PCR and antibody tests but with identified COVID exposure

within the four weeks prior to the onset of symptoms

HEALTH ALERT NETWO

Multisystem Inflammatory Syndrome in Children (MIS-C) The Overcoming COVID-19 Study

- Coordinated by Boston Children's Hospital, funded by CDC
- **213** MIS-C cases enrolled at 53 participating health centers in 26 states
- Most were previously healthy and cardiovascular involvement was prominent

Key findings	
SARS-CoV2 PCR+ or antibody positive at admission	73%
Age, median (IQR)	8.4 (3.6, 12.8)
<5 years	33%
5-21 years	67%
Previously healthy (except obesity)	73%
Male	63%
ICU	81%
Died	3%

81% cardiovascular involvement

50% with elevated troponin

38% with ejection fraction <55%

50% required vasopressor support

```
~9% had coronary aneurysms
(z-score ≥2.5)
has long-term implications
```

Next Steps:

Multisystem Inflammatory Syndrome in Children (MIS-C)

CDC MIS-C Surveillance

- CDC recommends that healthcare providers report suspect cases of MIS-C to local, state or territorial health departments
- Health departments then report cases the National Notifiable Diseases Surveillance System for case counts and case report forms are submitted using other MIS-C specific surveillance systems
- New Vaccine Surveillance Network
 - Seven US pediatric medical centers conducing active surveillance for acute respiratory and gastrointestinal illness
- COVID-NET
 - A population-based surveillance system collecting data on lab-confirmed SARS-CoV-2-associated hospitalizations among children



COVID-19 Epidemiology among Pregnant Women



1. 1

Pregnancy and risk for severe respiratory viral illness

Physiologic changes of pregnancy may increase the risk of severe illness ¹

- Increased heart rate and oxygen consumption
- Decreased lung capacity
- Shift away from cell-mediated immunity
- Severe disease has been associated with other viral respiratory infections in pregnant women¹⁻⁴



¹Ramsey PS et al. Pneumonia in pregnancy. Obstet Gynecol Clin North Am 2001



²Galang RR et al. Severe Coronavirus Infections in Pregnancy: A Systematic Review [online ahead of print, 2020 Jun 16]. Obstet Gynecol. 2020 ³Mertz D et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013 ⁴Mosby LG et al. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 2011

Pregnant Women: New York City



- Prospective cohort study of pregnant women with lab-confirmed SARS-CoV-2 from March 13–April 12 at 5 NYC medical centers
- 241 women with positive SARS-CoV-2 test
 - 89% admitted for obstetric indications
- 148 (61%) asymptomatic at time of admission
 - **46** developed COVID-19 symptoms during hospitalization
- Body mass index (BMI) ≥30 associated with COVID-19 severity
 - Insurance type, age, race and ethnicity, and underlying medical conditions not associated with COVID-19 severity



Pregnant Women: New York City




- 236/245 liveborn neonates with documented SARS-CoV-2 test results
 - 230 (98%) tested negative
- Preterm (<37 weeks gestation) birth rate in this cohort (14.6%) higher than in the general population (10.2%*)</p>
 - Statistically significant linear trend between COVID-19 maternal severity and the risk of preterm birth



*Martin J et al. Births in the United States, 2018. National Center for Health Statistics



Women of reproductive age (WRA) with SARS-CoV-2 infection by pregnancy status — Jan 22–Jun 7





Hospitalization, ICU admission, mechanical ventilation, and death among pregnant women and nonpregnant WRA with SARS-CoV-2 infection

	No. (%)*			
Outcomes of Interest	Pregnant women with COVID-19 (N = 8,207)	Nonpregnant women with COVID-19 (N = 83,205)	Crude RR (95% Cl)	aRR (95% CI) [†]
Hospitalization§	2,587 (31.5)	4,840 (5.8)	5.4 (5.2-5.7)	5.4 (5.1-5.6)
ICU Admission	120 (1.5)	757 (0.9)	1.6 (1.3-1.9)	1.5 (1.2-1.8)
Mechanical Ventilation	42 (0.5)	225 (0.3)	1.9 (1.4-2.6)	1.7 (1.2-2.4)
Death	16 (0.2)	208 (0.2)	0.8 (0.5-1.3)	0.9 (0.5-1.5)

* Percentages calculated among total in pregnancy status group; those with missing data on outcomes were counted as not having the outcome.

⁺ Adjusted for age as a continuous variable, dichotomous yes/no variable for presence of underlying conditions, and categorical race/ethnicity. Nonpregnant women are the referent group.

[§] May include women admitted for obstetric care reasons who receive routine SARS-CoV-2 testing upon admission.

Hospitalization Bias



- Challenges in interpretation of hospitalization as an outcome, since data are not available to determine whether hospitalization was due to COVID-19 or pregnancyrelated condition
- In an analysis of outcomes among pregnant versus non-pregnant women hospitalized with lab-confirmed COVID-19 from COVID-NET, the risk of ICU and mechanical ventilation was lower among pregnant compared to non-pregnant women, and there was no statistically significant difference in the risk of in-hospital death
 - Reason for admission is not specified; it is possible that non-pregnant women were predominately admitted for medical illness, whereas pregnant women admitted for medical illness or labor/delivery



 Pregnant women admitted solely for labor/delivery are likely healthier than pregnant or non-pregnant women admitted for medical illness





- Largest U.S. cohort of pregnant women with lab confirmed SARS-CoV-2 infection
- More complete data are needed to fully understand the risk of severe illness due to SARS-CoV-2 infection in pregnant women and neonates
- Results suggest an increased relative risk of ICU admission and mechanical ventilation comparing pregnant women with nonpregnant women; however, the absolute risk of these clinical interventions is still very low in this population



Next Steps: Pregnant Women

- Cohort studies, including retrospective electronic cohorts and prospective community cohorts
 - Assess incidence and seroprevalence of SARS-CoV-2 in pregnancy
 - Predictors for severity of disease
- Collecting surveillance data on pregnancy and neonatal outcomes
 - Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET)
- Leveraging existing pregnancy surveillance systems
 - Pregnancy Risk Assessment and Monitoring System (PRAMS)
 - COVID-NET





COVID-19 Epidemiology among People in Congregate Settings

• • • •

Congregate Settings: Meat & Poultry Processing

- 115 meat or poultry processing plants in 19 states reported COVID-19 cases to CDC in April 2020
- COVID-19 diagnosed in 4,913 (~3%) workers
 - By state, ranged from **0.6**% to **18.2**% of workers
- 20 COVID-19 related deaths reported





Congregate Settings: Correction & Detention Facilities

- 420 correctional/detention facilities with ≥1 COVID-19 case from 32 state and territorial health department jurisdictions
- COVID-19 diagnosed in 4,893 incarcerated persons and 2,778 staff
- 88 COVID-19 related deaths reported among incarcerated persons, 15 among staff





Congregate Settings: Homeless Shelters

- 1,192 residents and 313 staff members tested in 19 homeless shelters in 4 U.S. cities from March 27–April 15
- Homelessness poses multiple challenges that can amplify spread of COVID-19
 Shelters associated
 Shelters associated
 Shelters not associated
 with a cluster
 With a c

Seattle: **17%** positive Boston: **36%** positive San Francisco: **66%** positive

Seattle: **5%** positive Atlanta: **4%** positive





Serology



100 C 100 C

Seroprevalence Surveys



Large-scale geographic Seroprevalence Surveys: estimate the number of people previously infected with SARS-CoV-2 and not included in official case counts

Including specimens from commercial laboratories and blood donations

Community-level Seroprevalence Surveys: cover smaller areas, with selection of participants systematically selected






Summary





- ~2 million cases of COVID-19 diagnosed in the United States through June
- Multiple sub-populations appear to have an increased risk, including older adults, healthcare workers, individuals at long term care facilities or other congregate settings, and those with underlying medical conditions
- Many projects are ongoing to better define characteristics of SARS-CoV-2 infections





For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

